BrainZell
Relevant models for brain medicine with organoids technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
* | $1.5m | Seed | |
| Total Funding | 000k | ||
| SEK | 2021 | 2022 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| % profit margin | (168 %) | - |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
BrainZell is a pioneering startup operating in the pharmaceutical and biotechnology sector, with a specific focus on mental health and neurodegenerative disorders. The company's primary mission is to revolutionize the process of drug discovery for brain disorders, which currently has a success rate of only 6% in clinical trials. BrainZell's innovative approach involves the use of 'minibrains', organoids made from human cells that simulate certain functions of the human brain.
The company's target market includes the over 970 million people worldwide suffering from mental illnesses such as depression and schizophrenia, as well as the 50 million people affected by neurodegenerative disorders. BrainZell's services are also highly relevant to pharmaceutical companies seeking to improve the success rate of their clinical trials and make more informed business decisions.
BrainZell's business model is centered around providing a more effective and ethical alternative to traditional drug discovery methods. By using minibrains, the company aims to minimize the use of animals in clinical trials. This approach not only aligns with growing societal concerns about animal welfare but also promises to deliver more accurate results, given that minibrains more closely replicate human brain functions.
In terms of revenue generation, BrainZell likely charges pharmaceutical companies for its services, which include the production of minibrains and the provision of data and insights to support drug discovery and clinical trials.
Keywords: Biotechnology, Pharmaceutical, Mental Health, Neurodegenerative Disorders, Drug Discovery, Clinical Trials, Minibrains, Organoids, Animal Welfare, Business Decision Support.